NCT01162200已完成1 期
A Phase I Study of Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 75
- 试验地点
- 4
- 主要终点
- The maximum tolerated dose to the lumpectomy cavity in patients with early stage breast cancer
研究概览
简要总结
By using stereotactic body radiation therapy (SBRT) delivered with the Cyberknife system®, the current protocol attempts to mimic or improve the excellent local control rates seen in treatment of early stage breast cancer while attempting to increase convenience, limit invasiveness, decrease toxicity, and improve cosmesis compared to other methods of radiation treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DCIS or invasive ductal, medullary, papillary, mucinous (colloid), or tubular histologies.
- •Eligible patients must have appropriate staging studies identifying them as AJCC stage T1 or T2 (≤3 cm) treated with lumpectomy and axillary node dissection with at least 6 nodes sampled or sentinel node biopsy. Patients with up to 3 positive nodes without microscopic or macroscopic evidence of extracapsular extension are eligible.
- •The patient's Zubrod performance status must be 0-
- •Patients must be ≥ 18 years of age.
- •If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation therapy.
- •Unifocal breast cancer (no evidence of gross multifocal disease, multicentric, or bilateral disease.
- •Negative margins after lumpectomy (re-excision for initial positive margins is allowed-negative margins defined as >2 mm clear of tumor in all directions).
- •Negative post- lumpectomy mammography if malignancy-associated microcalcifications were initially present.
- •The target lumpectomy cavity must be clearly delineated.
- •Patients must complete appropriate pretreatment evaluation, including post-lumpectomy mammogram if microcalcifications were initially present to confirm complete removal.
排除标准
- •Evidence of suspicious microcalcifications in the breast prior to start of radiation.
- •Patients with history of collagen vascular disease, specifically dermatomyositis with a CPK level above normal or active skin rash, systemic lupus erythematosis, or scleroderma.
- •Patients with 4 or more histologically positive axillary nodes if axillary dissection is performed.
- •Patients with distant metastases.
- •Patients with invasive or extensive in-situ lobular carcinoma or non-epithelial breast malignancies such as sarcoma or lymphoma.
- •Patients with multicentric gross disease defined as tumors in different quadrants of the breast or tumor separated by at least 4 cm or other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy or biopsy.
- •Patients must not have any palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes unless there is histologic confirmation that these nodes are negative for tumor.
- •Any previously treated contralateral invasive breast carcinoma or synchronous contralateral breast carcinoma.
- •Prior non-hormonal therapy or radiation therapy for the current breast cancer or hormonal therapy for > 28 days after diagnosis or refusal to discontinue hormonal therapy.
- •Patients with Paget's disease of the nipple
- •Patients with prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (e.g., carcinoma in situ of the breast, oral cavity, or cervix are all permissible).
- •Patients with severe, active co-morbidity.
- •Patients with psychiatric or addictive disorders that, in the opinion of the investigator, would preclude obtaining informed consent.
- •Patients who are pregnant or lactating.
- •Previous breast radiation on either side or thoracic radiation on the ipsilateral side..
结局指标
主要结局
The maximum tolerated dose to the lumpectomy cavity in patients with early stage breast cancer
时间窗: 3 years
To escalate the dose of stereotactic radiotherapy utilizing the Cyberknife system to a tumorcidal dose to the lumpectomy cavity without exceeding the maximum tolerated dose in patients with early stage breast cancer.
次要结局
- The cosmesis of breast(3 years)
- Dose-limiting toxicity(3 years)
研究者
研究点 (4)
Loading locations...
相似试验
撤回
不适用
A Pilot Study of CyberKnife Radiosurgery Delivered to the Partial BreastBreast CancerNCT00529334Georgetown University
已完成
不适用
Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast CancerBreast CancerNCT01290835Essentia Health20
尚未招募
不适用
Short course radiation therapy by Cyberknife for early breast cancersCTRI/2013/10/004041Medanta the Medicity24
已完成
不适用
Cyberknife for Early Stage Breast CancerEarly Stage Breast CancerNCT03946683NYU Langone Health26
Unknown
不适用
Cyberknife After Breast Conservative SurgeryBreast CancerNCT02896322Fondazione IRCCS Istituto Nazionale dei Tumori, Milano80